Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Infections and Infectious Diseases Phase I/ Phase II
Canada 
Details:
AP-003 is an anti-viral, recombinant human interferon alpha-2b product proven to be an effective treatment against COVID-19 successfully completed the Phase 1 portion of the Phase 1-2 randomized placebo controlled trial.
Lead Product(s): Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2021
Details:
Studies are ongoing to validate preliminary results and to test rhIFN⍺2b activity against Gamma (Brazil), Lambda (Peru), and the recent C.1.2 (South Africa) variant which contains mutations associated with increased transmissibility and the ability to evade antibodies therapy.
Lead Product(s): Interferon Alfa-2B
Therapeutic Area: Infections and Infectious Diseases Product Name: AP-003
Highest Development Status: Phase I/ Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
